Form 4: Olema CEO Bohen Granted 1.125M Stock Options

Olema Pharmaceuticals' President and CEO, Sean Bohen, was granted 1,125,000 stock options, including performance-based awards, effective February 2, 2026.

Summary

• Sean Bohen, President and CEO of Olema Pharmaceuticals, Inc., was granted a total of 1,125,000 stock options.
• This includes 850,000 time-based stock options with an exercise price of $25.65.
• The time-based options vest 25% on February 2, 2027, and 1/48th of the total shares each month thereafter, contingent on continuous service.
• An additional 275,000 performance-based stock options were granted, also with an exercise price of $25.65.
• These performance options are eligible to vest based on the Issuer's stock price reaching pre-determined thresholds over two distinct periods: February 2, 2026, to December 31, 2029, and February 2, 2026, to December 31, 2030.
• If Bohen's service is terminated without Cause, the performance-based options remain outstanding and eligible to vest for 12 months post-termination.
• All options have an expiration date of February 1, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns the CEO's long-term incentives with shareholder value through significant equity grants, including performance-based options. The fixed exercise price means value is tied to future stock appreciation.

Positives

• The grant of a significant number of stock options (1,125,000 shares) aligns management's incentives with long-term shareholder value creation.
• Performance-based options (275,000 shares) directly link a portion of the CEO's compensation to the achievement of specific stock price thresholds, indicating a focus on share price appreciation.
• The extended eligibility for performance options post-termination without Cause provides some retention incentive and protection for the CEO.

Negatives

• The exercise price of $25.65 for both types of options is a fixed value, meaning the options only have intrinsic value if the stock price rises above this level.
• The vesting schedule for time-based options is back-loaded, with the first 25% vesting a year after the grant date, which could be seen as a longer wait for initial equity realization.

Risks

• The value of the stock options is entirely dependent on the future performance of Olema Pharmaceuticals' stock price. If the stock price does not exceed the exercise price of $25.65, the options may expire worthless.
• Performance-based options carry the risk that the pre-determined stock price thresholds may not be met within the specified performance periods, leading to forfeiture of those options.
• The vesting of both time-based and performance-based options is contingent on the Reporting Person's continuous service, introducing a risk of forfeiture if service is terminated for cause or voluntarily.

Future Outlook

The grant of performance-based stock options tied to specific stock price thresholds indicates management's forward-looking strategy to drive share price appreciation over the next several years, with performance periods extending through December 31, 2030.

Industry Context

StockSavvy.ai notes that granting substantial equity awards, particularly those with performance-based vesting conditions, is a common practice in the biotechnology and pharmaceutical sectors. This strategy aims to align executive incentives with long-term shareholder value creation, which is crucial in an industry characterized by high R&D costs and lengthy development cycles. Such grants are often seen as a mechanism to retain key talent and motivate leadership to achieve significant milestones, such as clinical trial successes or market approvals, which directly impact stock performance.

Stakeholder Impact

• Shareholders: Potential positive impact if the CEO's incentivized performance leads to increased stock value. Dilution risk from future option exercises, though this is standard for equity compensation.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.
• Management: Strong incentive to drive stock price appreciation and ensure continuous service to realize the value of the options.

Next Steps

• Continued service by Sean Bohen to meet vesting conditions for both time-based and performance-based stock options.
• Olema Pharmaceuticals' stock price performance will be monitored against pre-determined thresholds for the vesting of performance-based options.
• The Compensation Committee will certify the achievement of stock price thresholds for performance-based options.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event through stock option grants. While the grants align management incentives with shareholder value, they do not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Investors should continue to hold based on existing fundamentals and broader market conditions, awaiting more substantive operational or financial updates.

Keywords

Olema Pharmaceuticals, OLMA, Stock Options, Performance Options, Executive Compensation, Sean Bohen, Form 4, Insider Transaction, Equity Grant, Biotechnology